Aset Therapeutics
Stony Brook, US · Founded 2016 · Delaware corporation · 4 known investors
Find your way into Aset Therapeutics
348 people in our graph share verified history with the Aset Therapeutics team — schools, employers, funds. One of them is your warm intro.
Kevin Gillisunlockedknows David M Epstein · together at Brandeis University (overlapped)
×8knows the team · via Brandeis University
×2knows the team · via Bayer
knows the team · via Duke-NUS Medical School
Founders & leadership
EB
Elizabeth BuckinExecutive
DM
David M EpsteininExecutiveHe holds a Ph.D. from Brandeis University and B.S. in Chemistry from Lewis & Clark College, with postdoctoral training in protein NMR at The Scripps Research Institute. He previously served as Chief Scientific Officer at OSI Pharmaceuticals (acquired by Astellas in 2010), co-founded Archemix (which developed avacincaptad pegol for age-related macular degeneration), founded Black Diamond Therapeutics where he led oncology drug programs through clinical development, and is currently leading PairX Bio.
Board
BB
AM
GE
Garry E MenzelBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$146.3M disclosed across 4 rounds · 2017–2019
▶$85MraisedDec 2019 · 28 investors · BiotechnologyRule 506(b)
▶$85MraisedDec 2019 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David M. EpsteinExecutive Officer, Director
- Thomas LeggettExecutive Officer
- Brent Hatzis-SchochExecutive Officer
- Christopher RobertsExecutive Officer
- Ali BehbahaniDirector
- Rajeev ShahDirector
- Garry MenzelDirector
- Alexander MaywegDirector
- Bradley BolzonDirector
- Samarth KulkarniDirector
- Offering amount
- $85M
- Amount sold
- $85M
- First sale
- Nov 2019
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$44.2MraisedJul 2019 · 16 investors · BiotechnologyRule 506(b)
▶$44.2MraisedJul 2019 · 16 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Rajeev ShahDirector
- Ali BehbahaniDirector
- Fang NiExecutive Officer
- Elizabeth BuckExecutive Officer
- Alexander MaywegDirector
- Brent Hatzis-SchochExecutive Officer
- Garry E. MenzelDirector
- Bradley BolzonDirector
- David M. EpsteinExecutive Officer, Director
- Offering amount
- $87.2M
- Amount sold
- $44.2M
- First sale
- Dec 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$5MraisedAug 2018 · 1 investors · BiotechnologyRule 506(b)
▶$5MraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elizabeth BuckExecutive Officer
- David M. EpsteinExecutive Officer, Director
- Alexander MaywegDirector
- Garry E. MenzelDirector
- Bradley BolzonDirector
- Offering amount
- $10M
- Amount sold
- $5M
- First sale
- Aug 2018
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
▶$12.1MraisedJan 2018 · 11 investors · BiotechnologyRule 506(b)
▶$12.1MraisedJan 2018 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Elizabeth BuckExecutive Officer
- Garry E MenzelDirector
- David M EpsteinExecutive Officer, Director
- Brad BolzonDirector
- Alexander MaywegDirector
- Offering amount
- $12.1M
- Amount sold
- $12.1M
- First sale
- Mar 2017
- Incorporated
- Corporation, Delaware, 2016
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- Who are Aset Therapeutics's investors?
- Aset Therapeutics's investors include New Enterprise Associates (NEA), Nextech Invest, RA Capital, Versant Ventures.
- How much funding has Aset Therapeutics raised?
- Aset Therapeutics has disclosed $146.3M raised across 4 rounds.
- Where is Aset Therapeutics headquartered?
- Aset Therapeutics is headquartered in Stony Brook, US.